ReviewClinical cancer research : an official journal of the American Association for Cancer Research2013
Molecular pathways: ROS1 fusion proteins in cancer.
Review in Clinical cancer research : an official journal of the American Association for Cancer Research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 197 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
197 citing papers in PubMed, 2 syntheses or guidelines pooled it, 370 citations in OpenAlex.
- Toxicity profiles of ROS1 tyrosine kinase inhibitors in advanced non-small cell lung cancer: a systematic review and proportional meta-analysis.Frontiers in pharmacology · 2025Pooled it
- Recurrence of Epithelioid Hemangioendothelioma during Pregnancy: Case Report and Systematic Review.The Permanente journal · 2016Pooled it
- Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial.Nature medicine · 2024Trial
- Effect of High-Fat Food on the Pharmacokinetic Profile and Safety of SAF-189s, an ALK/ROS1 Inhibitor, in Healthy Chinese Adults.Drugs in R&D · 2023Trial
- Trial
- Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer.The oncologist · 2016Trial
- ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.Molecular cancer research : MCR · 2014Trial
- Penile Metastasis From Castration-Resistant Prostate Cancer: A Case Report.IJU case reports · 2026Article
- Functional Depth Biomarkers Distinguish Lung Squamous Cell Carcinoma from Lung Adenocarcinoma.Research square · 2026Article
- Targeting non-small cell lung cancer: Molecular mechanisms and clinical studies (Review).Oncology letters · 2026Review
- Article
- Prognostic value of ROS1 rearrangement in lung adenocarcinoma stratified by clinicopathologic and radiological features: a retrospective cohort study.Translational lung cancer research · 2026Article
- Entrectinib-Induced Sinus Bradycardia in a Patient With Metastatic Non-Small Cell Lung Cancer.JACC. Case reports · 2026Article
- Whole-genome combinatorial gene fusions generate novel genes for advanced microbial trait development.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Single-cell eQTL mapping reveals cell-type-specific genetic regulation in lung cancer.Cell genomics · 2026Article
- Optogenetic Translocation to Subcellular Compartments through Regulation of Protein Avidity.ACS synthetic biology · 2026Article
- Review
- Molecular Docking and MD Modeling Techniques for the Development of Novel ROS1 Kinase Inhibitors.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Novel Pattern of Nuclear Staining With ROS1 Immunohistochemistry: A Case Report.Case reports in pulmonology · 2026Article
- Genomic alterations linked to recurrence risk in high-grade serous ovarian cancer revealed by deep targeted sequencing.Scientific reports · 2025Article
137 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Genetic alterations that lead to constitutive activation of kinases are frequently observed in cancer. In many cases, the growth and survival of tumor cells rely upon an activated kinase such that inhibition of its activity is an effective anticancer therapy. ROS1 is a receptor tyrosine kinase that has recently been shown to undergo genetic rearrangements in a variety of human cancers, including glioblastoma, non-small cell lung cancer (NSCLC), cholangiocarcinoma, ovarian cancer, gastric adenocarcinoma, colorectal cancer, inflammatory myofibroblastic tumor, angiosarcoma, and epithelioid hemangioendothelioma. These rearrangements create fusion proteins in which the kinase domain of ROS1 becomes constitutively active and drives cellular proliferation. Targeting ROS1 fusion proteins with the small-molecule inhibitor crizotinib is showing promise as an effective therapy in patients with NSCLC whose tumors are positive for these genetic abnormalities. This review discusses the recent preclinical and clinical findings on ROS1 gene fusions in cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.